Neurobehavioral Disorders
Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.
Neurobehavioral Disorders
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Neurobehavioral Disorders
For patients with MDD, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram.
Alzheimer's Disease and Dementia
For people with dementia with symptoms of depression, without a MDD, nondrug interventions are more efficacious than drug interventions.
Alzheimer's Disease and Dementia
The researchers sought to estimate the age-specific incidence and prevalence of dementia diagnoses among older adults with schizophrenia in the United States compared to those without serious mental illness.
Multiple Sclerosis
A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.
Neurobehavioral Disorders
More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.
Neurobehavioral Disorders
Researchers from Dalhousie University in Canada searched publication databases through September of 2020 for articles on ADHD, attention deficit disorder, bipolar disorder, and affective psychosis.
Neurobehavioral Disorders
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
Epilepsy
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
